Higher TIGIT⁺CD226^- γδ T cells in Patients with Acute Myeloid Leukemia

References

• Alnaggar M, Xu Y, Li J, He J, Chen J, Li M, Wu Q, Lin L, Liang Y, Wang X, et al. 2019. Allogenic Vgamma9Vdelta2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma. J Immunother Cancer. 7:36.
   PubMed Web of Science ®Google Scholar
• Belkina AC, Starchenko A, Drake KA, Proctor EA, Pihl RMF, Olson A, Lauffenburger DA, Lin N, Snyder-Cappione JE. 2018. Multivariate computational analysis of gamma delta T cell inhibitory receptor signatures reveals the divergence of healthy and ART-suppressed HIV+ aging. Front Immunol. 9:2783.
   PubMed Web of Science ®Google Scholar
• Born WK, Reardon CL, O’Brien RL. 2006. The function of gammadelta T cells in innate immunity. Curr Opin Immunol. 18:31–38.
   PubMed Web of Science ®Google Scholar
• Chen C, Liang C, Wang S, Chio CL, Zhang Y, Zeng C, Chen S, Wang C, Li Y. 2020. Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 13:28.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al. 2017. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 129:424–47.
   PubMed Web of Science ®Google Scholar
• Dong Q, Cai C, Gao F, Chen P, Gong W, Shen M. 2019. Defective Treg response in acute kidney injury was caused by a reduction in TIM-3+ Treg cells. Immunol Invest. 48:27–38.
   PubMed Web of Science ®Google Scholar
• Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. 2014. gammadelta T cells for cancer immunotherapy: A systematic review of clinical trials. Oncoimmunology. 3:e27572.
   PubMed Web of Science ®Google Scholar
• Hattori N, Kawaguchi Y, Sasaki Y, Shimada S, Murai S, Abe M, Baba Y, Watanuki M, Fujiwara S, Arai N, et al. 2019. Monitoring TIGIT/DNAM-1 and PVR/PVRL2 immune checkpoint expression levels in allogeneic stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant. 25:861–67.
   PubMed Web of Science ®Google Scholar
• Hoeres T, Holzmann E, Smetak M, Birkmann J, Wilhelm M. 2019. PD-1 signaling modulates interferon-gamma production by Gamma Delta (gammadelta) T-Cells in response to leukemia. Oncoimmunology. 8:1550618.
   PubMed Web of Science ®Google Scholar
• Huang G, Zhang Y, Wei X, Yu Z, Lai J, Shen Q, Chen X, Tan G, Chen C, Luo W, et al. 2020. CD8(+) GITR(+) T cells may negatively regulate T cell overactivation in aplastic anemia. Immunol Invest. 1–10. doi:https://doi.org/10.1080/08820139.2020.1770785
   Google Scholar
• Huang J, Tan J, Chen Y, Huang S, Xu L, Zhang Y, Lu Y, Yu Z, Chen S, Li Y. 2019. A skewed distribution and increased PD-1+Vbeta+CD4+/CD8+ T cells in patients with acute myeloid leukemia. J Leukoc Biol. 106:725–32.
   PubMed Web of Science ®Google Scholar
• Jin Z, Luo Q, Lu S, Wang X, He Z, Lai J, Chen S, Yang L, Wu X, Li Y. 2016. Oligoclonal expansion of TCR Vdelta T cells may be a potential immune biomarker for clinical outcome of acute myeloid leukemia. J Hematol Oncol. 9:126.
   PubMed Web of Science ®Google Scholar
• Kasakovski D, Xu L, Li Y. 2018. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 11:91.
   PubMed Web of Science ®Google Scholar
• Kearney CJ, Ramsbottom KM, Voskoboinik I, Darcy PK, Oliaro J. 2016. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing. Oncoimmunology. 5:e1196308.
   PubMed Web of Science ®Google Scholar
• Knight A, Mackinnon S, Lowdell MW. 2012. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy. 14:1110–18.
   PubMed Web of Science ®Google Scholar
• Kong Y, Jia B, Zhao C, Claxton DF, Sharma A, Annageldiyev C, Fotos JS, Zeng H, Paulson RF, Prabhu KS, et al. 2019. Downregulation of CD73 associates with T cell exhaustion in AML patients. J Hematol Oncol. 12:40.
   PubMed Web of Science ®Google Scholar
• Lawand M, Dechanet-Merville J, Dieu-Nosjean MC. 2017. Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications. Front Immunol. 8:761.
   PubMed Web of Science ®Google Scholar
• Li M, Yao D, Zeng X, Kasakovski D, Zhang Y, Chen S, Zha X, Li Y, Xu L. 2019. Age related human T cell subset evolution and senescence. Immun Ageing. 16:24.
   PubMed Web of Science ®Google Scholar
• Li Y, Sun R. 2018. Tumor immunotherapy: new aspects of natural killer cells. Chin J Cancer Res. 30:173–96.
   PubMed Web of Science ®Google Scholar
• Liu D. 2019. Cancer biomarkers for targeted therapy. Biomarker Res. 7:25.
   PubMed Web of Science ®Google Scholar
• Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. 2019. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? Blood Rev. 34:67–83.
   PubMed Web of Science ®Google Scholar
• Mastaglio S, Wong E, Perera T, Ripley J, Blombery P, Smyth MJ, Koldej R, Ritchie D. 2018. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Adv. 2:335–46.
   PubMed Web of Science ®Google Scholar
• Rossi C, Gravelle P, Decaup E, Bordenave J, Poupot M, Tosolini M, Franchini DM, Laurent C, Morin R, Lagarde JM, et al. 2019. Boosting gammadelta T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. Oncoimmunology. 8:1554175.
   PubMed Web of Science ®Google Scholar
• Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Banas H, Casas-Aviles I, Duran E, et al. 2019. DNAM-1 and the TIGIT/PVRIG/TACTILE axis: novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers (Basel). 11:877.
   Web of Science ®Google Scholar
• Shibuya K, Shirakawa J, Kameyama T, Honda S, Tahara-Hanaoka S, Miyamoto A, Onodera M, Sumida T, Nakauchi H, Miyoshi H, et al. 2003. CD226 (DNAM-1) is involved in lymphocyte function-associated antigen 1 costimulatory signal for naive T cell differentiation and proliferation. J Exp Med. 198:1829–39.
   PubMed Web of Science ®Google Scholar
• Stamm H, Oliveira-Ferrer L, Grossjohann EM, Muschhammer J, Thaden V, Brauneck F, Kischel R, Muller V, Bokemeyer C, Fiedler W, et al. 2019. Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. Oncoimmunology. 8:e1674605.
   PubMed Web of Science ®Google Scholar
• Stein N, Tsukerman P, Mandelboim O. 2017. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies. Hum Antibodies. 25:111–19.
   PubMedGoogle Scholar
• Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, et al. 2019. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J National Compr Cancer Netw. 17:721–49.
   PubMed Web of Science ®Google Scholar
• Tan J, Chen S, Lu Y, Yao D, Xu L, Zhang Y, Yang L, Chen J, Lai J, Yu Z, et al. 2017. Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia. Chin J Cancer Res. 29:463–70.
   PubMed Web of Science ®Google Scholar
• Tan J, Huang S, Huang J, Yu Z, Chen Y, Lu Y, Li Y, Chen S. 2020. Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T cells in patients with acute myeloid leukemia. Asia Pac J Clin Oncol. doi:https://doi.org/10.1111/ajco.13304
   Google Scholar
• Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G, Lin Q, Xu X, Leavenworth JW, Shen E. 2018. CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol. 190:64–73.
   PubMed Web of Science ®Google Scholar
• Wang X, Li Y. 2019. Extensive exploration of T cell heterogeneity in cancers by single cell sequencing. Chin J Cancer Res. 31:410–18.
   PubMed Web of Science ®Google Scholar
• Wang X, Mou W, Han W, Xi Y, Chen X, Zhang H, Qin H, Wang H, Ma X, Gui J. 2019. Diminished cytolytic activity of γδ T cells with reduced DNAM-1 expression in neuroblastoma patients. Clin immunol (Orlando, Fla). 203:63–71.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. 2011. T cell exhaustion. Nat Immunol. 12:492–99.
   PubMed Web of Science ®Google Scholar
• Wu K, Zhao H, Xiu Y, Li Z, Zhao J, Xie S, Zeng H, Zhang H, Yu L, Xu B. 2019. IL-21-mediated expansion of Vgamma9Vdelta2 T cells is limited by the Tim-3 pathway. Int Immunopharmacol. 69:136–42.
   PubMed Web of Science ®Google Scholar
• Xu L, Weng J, Huang X, Zeng C, Chen S, Geng S, Yang L, Wu S, Huang S, Du X, et al. 2016. Persistent donor derived Vdelta4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI. Oncotarget. 7:42943–52.
   PubMedGoogle Scholar
• Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al. 2009. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 10:48–57.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang J, Zhou J, Gao W, Zhang Y, Lin Y, Wang H, Ruan Z, Ni B. 2019. Prognostic values of CD38+CD101+PD1+CD8+ T cells in pancreatic cancer. Immunol Invest. 48:466–79.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li Y. 2019. T cell receptor-engineered T cells for leukemia immunotherapy. Cancer Cell Int. 19:2.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Niu C, Cui J. 2018. Gamma-delta (gammadelta) T cells: friend or foe in cancer development? J Transl Med. 16:3.
   PubMed Web of Science ®Google Scholar
• Zhou X, Ding X, Li H, Yang C, Ma Z, Xu G, Yang S, Zhang D, Xie X, Xin L, et al. 2020. Upregulation of TIGIT and PD-1 in colorectal cancer with mismatch-repair deficiency. Immunol Invest. 1–18. doi:https://doi.org/10.1080/08820139.2020.58130
   Google Scholar